Readily isolated bispecific antibodies with native immunoglobulin format

Patent metadata

Field	Value
Publication number	US-9815909-B2
Application number	US-201313798485-A
Country	US
Kind code	B2
Filing date	Mar 13, 2013
Priority date	Mar 13, 2012
Publication date	Nov 14, 2017
Grant date	Nov 14, 2017

Abstract

The invention relates to antigen-binding proteins or antibodies having heterodimers of heavy chains, i.e., two immunoglobulin heavy chains that differ by at least one or two amino acid(s) that allows for isolation of the antigen-binding protein based on a differential affinity of an immunoglobulin heavy chain and a modified/mutated immunoglobulin heavy chain toward an affinity reagent. The invention also relates antigen-binding proteins, including bispecific antibodies, having IgG CH1 regions with different affinities with respect to affinity reagent(s) that allows rapid isolation by differential binding of the IgG regions to the affinity reagent(s).

First claim

What is claimed is:

1. A method for isolating a bispecific antibody comprising:
a) obtaining a nucleic acid sequence encoding a first immunoglobulin heavy chain comprising a first variable region that binds a first epitope, wherein the first immunoglobulin heavy chain comprises an IgG1 isotype constant domain comprising the amino acid sequence of SEQ ID NO: 1, an IgG2 isotype constant domain comprising the amino acid sequence of SEQ ID NO: 2, an Ig3 isotype constant domain comprising the amino acid sequence of SEQ ID NO: 3, or an IgG4 isotype constant domain comprising the amino acid sequence of SEQ ID NO: 4;
b) obtaining a second nucleic acid sequence encoding a second immunoglobulin heavy chain comprising a second variable region that binds a second epitope, wherein the second immunoglobulin heavy chain comprises a second IgG1, IgG2, IgG3 or IgG4 isotype constant domain that comprises a modification in its CH1 domain that eradicates or reduces binding to an affinity reagent targeting the human IgG1, IgG2, IgG3 and IgG4 CH1 domain, wherein the second IgG1 isotype constant domain comprises the amino acid sequence of SEQ ID NO: 15 the second IgG2 isotype constant domain comprises the amino acid sequence of SEQ ID NO: 16, the second IgG3 isotype constant domain comprises the amino acid sequence of SEQ ID NO: 17, or the second IgG4 isotype constant domain comprises the amino acid sequence of SEQ ID NO: 18:
c) obtaining a third nucleic acid sequence encoding an immunoglobulin light chain that pairs with the first and the second immunoglobulin heavy chain;
d) introducing the first, second, and third nucleic acid sequences into a mammalian cell;
e) allowing the cell to express a bispecific antibody; and
f) isolating the bispecific antibody based on the ability of the bispecific antibody to bind the affinity reagent targeting the human IgG1, IgG2, IgG3 and IgG4 CH1 domain.

2. The method of claim 1 , wherein the first immunoglobulin heavy chain, the second immunoglobulin heavy chain or both the first and second immunoglobulin heavy chains are non-immunogenic in a human.

3. The method of claim 1 , where the bispecific antibody is isolated on a solid support an IgG-CH1 affinity column targeting the human IgG1, IgG2, IgG3 and IgG4 CH1 domain.

4. The method of claim 3 , wherein the bispecific antibody is isolated employing a pH gradient.

5. The method of claim 4 , wherein the pH gradient is a step gradient comprising one or more pH steps between pH 3 and pH 5.

6. The method of claim 1 , wherein the first immunoglobulin heavy chain comprises a mutation altering its binding properties to Protein A.

7. The method of claim 6 , wherein the mutation comprises a H435R mutation.

8. A method for isolating a bispecific antibody, comprising:
a) contacting a disrupted cell or a mixture of antibodies comprising a bispecific antibody having a differentially modified IgG1 CH1 domains with an affinity reagent targeting a human IgG1 CH1 domain, wherein the differentially modified CH1 domains are non-immunogenic in a human, wherein the differentially modified CH1 domains result in a bispecific antibody with a heterodimeric heavy chain constant region whose monomers have a differential affinity for affinity reagent targeting the human IgG1 CH1 domain, and wherein one of the monomer of the heterodimeric heavy chain constant region is a human IgG1 comprising the amino acid sequence of SEQ ID NO: 1, and the other monomer of the heterodimeric heavy chain constant region is a modified human IgG1 comprising the amino acid sequence of SEQ ID NO: 15; and
b) isolating the bispecific antibody from the disrupted cell or mixture based on the ability of the bispecific antibody to bind to the affinity reagent targeting the human IgG1 CH1 domain.

9. The method of claim 8 , wherein the first immunoglobulin heavy chain comprises a mutation altering its binding properties to Protein A.

10. The method of claim 9 , wherein the first immunoglobulin heavy chain comprises a H435R mutation.

Assignees

• Novimmune Sa

Inventors

• Fischer Nicolas
• Magistrelli Giovanni
• Rousseau Francois
• Masternak Krzysztof
• Malinge Pauline

Classifications

• C07K2317/31

  multispecific · CPC title

• C07K16/244 Primary

  Interleukins [IL] · CPC title

• C07K16/2809

  against the T-cell receptor (TcR)-CD3 complex · CPC title

• C07K16/468 Primary

  Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies · CPC title